Log in or register to see all Alerts
New HTA Decisions in England
August 2020
Drug name
ADCETRIS® (brentuximab vedotin)
Decision date
Therapeutic area
Therapeutic sub area
Blood and bone marrow cancers
Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is recommended, within its marketing authorisation, as an option for untreated systemic anaplastic large cell lymphoma in adults.
Decision Detail
It is only recommended if the company provides brentuximab vedotin according to the commercial arrangement. There is a simple discount patient access scheme for brentuximab vedotin.
The clinical evidence for brentuximab vedotin with CHP came from ECHELON 2, a randomised controlled trial of 452 people with CD30-positive peripheral T cell lymphoma, comparing brentuximab vedotin and CHP with CHOP. Brentuximab vedotin with CHP statistically significantly reduced the risk of a progression event compared with CHOP (stratified hazard ratio [HR] 0.59 [95% CI 0.42 to 0.84]; p=0.0031). Overall survival was also statistically significantly improved for brentuximab vedotin with CHP compared with CHOP (HR 0.54 [95% CI 0.337 to 0.867], p=0.0096). The committee concluded that brentuximab vedotin with CHP improves progression-free survival and overall survival compared with current standard care, CHOP. The committee concluded that there were considerable uncertainties about how the company modelled progression-free survival and overall survival. The most plausible ICER for brentuximab vedotin plus CHP compared with CHOP was £23,446 per QALY gained (including the simple discount patient access scheme). The committee concluded that brentuximab vedotin with CHP could be considered a cost-effective use of NHS resources. Therefore, it was recommended as an option for untreated sALCL.